Lacosamid Hameln (Lacosamide)

Lacosamide is used as adjunctive therapy in the management of partial‑onset seizures, a type of focal epilepsy.

• Partial‑onset seizures: reduces seizure frequency when added to existing antiepileptic therapy.
• Focal epilepsy: provides adjunctive seizure control in patients not fully controlled by other medications.
• Refractory focal seizures: used as an additional option when seizures persist despite standard treatment.

• Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, stabilizing neuronal membranes and reducing hyperexcitability. It also binds to collapsin response mediator protein‑2 (CRMP2), further modulating neuronal signaling pathways involved in seizure generation.

Lacosamide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness.
• Nausea: feeling of queasiness or urge to vomit.
• Headache: mild to moderate cranial pain.
• Fatigue: unusual tiredness or lack of energy.

Serious or Rare Side Effects

• Cardiac conduction abnormalities: PR‑interval prolongation that may lead to arrhythmia.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Suicidal thoughts: emergence of depressive symptoms or suicidal ideation.
• Respiratory depression: marked reduction in breathing effort, especially with concomitant CNS depressants.

When using Lacosamide, several safety considerations should be observed.

• Renal impairment: monitor renal function and adjust therapy as needed.
• Hepatic impairment: use with caution and observe liver enzymes.
• Concomitant antiepileptic drugs: assess for additive CNS effects.
• Pregnancy: limited data; weigh potential benefits against risks.
• Cardiac conduction: obtain baseline ECG and monitor for PR prolongation.
• Store at ambient temperature: keep in original container, protect from light and moisture.

Lacosamide can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may markedly reduce lacosamide plasma levels.
• Drugs that prolong PR interval (e.g., quinidine, amiodarone): increase risk of cardiac conduction delay.
• Concomitant use with other sodium‑channel blockers (e.g., lamotrigine) at high doses: may enhance adverse CNS effects.

Moderate Interactions (Monitor Closely)

• Valproate: may increase lacosamide concentrations, requiring dose review.
• Alcohol: can potentiate central nervous system depression, leading to increased drowsiness.
• Other antiepileptics (e.g., levetiracetam, topiramate): may require monitoring for additive side effects.